GenomeQuest Adds China Sequence Patents to IP Research Solution
News Dec 06, 2010
Already, over 40,000 sequences from over 5000 Chinese patents are indexed and searchable in GQ-IP, the company’s online patent research solution that now holds information on over 300,000 patents globally.
“Our preliminary analysis indicates that over 50% of Chinese patents with biological sequences are not filed in other country or international patent databases outside of SIPO,” said Kamalakar Gulukota, GenomeQuest Product Evangelist. “If your invention will be marketed in China, including SIPO in your patent search is required to ascertain the total patent landscape around your sequence.”
Indexed sequences from SIPO patent filings are immediately available to GQ-IP users. For more details on pricing, please contact GenomeQuest sales at firstname.lastname@example.org.
More on GQ-IP
GQ-IP is an online patent research solution with easy-to-use, comprehensive content, search, and analysis tools.
GQ-IP aggregates, normalizes, curates, and updates patent information across global databases, including USPTO, EPO, WIPO & PCT, INPADOC, GenBank, EMBL, DDBJ, and paper filings from WIPO. Over 300,000 patents -- including their sequences and all annotations -- are now stored and updated bi-weekly in the GQ-IP database. Annotations include patent number, title, abstract, assignee, inventors, dates, and patent families. Users can also add in-house sequence data to GQ-IP.
GQ-IP search tools offer multiple search algorithms, including BLAST, GenePast, and more that work across their selected set of global databases. The GQ-IP result browser allows users to interactively query/filter/group on any field, and to quickly pinpoint matches of most interest. Multiple users can collaborate on shared datasets. GQ-IP also offers a comprehensive set of patent search reports.
Law firms, pharmaceutical firms, biotech companies, and academia use GQ-IP as an integrated solution for all their patent sequence searching needs: including for IP validity, freedom-to-operate, patent infringement, and business opportunity. Major benefits include: higher productivity, integrated global content, higher quality of results, and zero IT costs and administration. For more information visit http://www.genomequest.com/workflows/patent-search/.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE